As of September 2021, high-income countries accounted for around 80 percent of total Pfizer/BioNTech vaccines delivered worldwide. The statistic illustrates the share of Pfizer/BioNTech COVID-19 vaccines delivered worldwide as of September 2021, by country income group.

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Moderna Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

In November 2020, COVID-19 vaccines from the Biontech/Pfizer cooperation and from Moderna showed very good results in phase III of clinical trials. Both sites reported nearly the exact same efficacy of around 95 percent. Pfizer and BioNTech will probably be able to produce larger amounts until year-end 2020 and also during 2021.

A phase 1/2, open-label clinical trial in individuals, 18 years of age and older, who are in good health, have no known history of Coronavirus Disease 2019 (COVID-19) or Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and meet all other eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of a delayed (>/=12 weeks) vaccine boost on a range of Emergency Use Authorization (EUA)-dosed COVID-19 vaccines (mRNA-1273, and mRNA-1273.211 manufactured by ModernaTX, Inc.; BNT162b2 manufactured by Pfizer/BioNTech; or Ad26.COV2.S manufactured by Janssen Pharmaceuticals/Johnson & Johnson). This is an adaptive design and may add arms (and increase sample size) as vaccines are awarded EUA and/or variant lineage spike vaccines are manufactured or become available. Enrollment will occur at up to twelve domestic clinical research sites.

This study includes two cohorts. Cohort 1 will include approximately 880 individuals (50 subjects/group; Groups 1E-11E) greater than 18 years of age and older, stratified into two age strata (18-55 years and >/=56 years) who previously received COVID-19 vaccine at Emergency Use Authorization dosing (EUA) (two vaccinations of mRNA-1273 at the 100 mcg dose, two vaccinations of BNT162b2 at the 30 mcg dose, or one vaccination of Ad26.COV2.S at the 5x10^10 vp dose). Groups 15E-17E will enroll 60 subjects, split (approximately evenly) between age strata as able. Those subjects will be offered enrollment into this study >/=12 weeks after they received the last dose of their EUA vaccine. Subjects will receive a single open-label intramuscular (IM) injection of the designated delayed booster vaccine and will be followed through 12 months after vaccination: 1) Group 1E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp followed by a 100-mcg dose of mRNA-1273, Group 4E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 7E - previously EUA-dosed vaccination with Janssen - Ad26.COV.2.S 5x10^10 vp followed by a 30-mcg dose of BNT162b2, Group 10E - previously EUA-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp followed by a 100-mcg dose of mRNA-1273.211; Group 12E - previously EUA-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp followed by a 50-mcg dose of mRNA-1273; Group 15E - previously EUA-dosed vaccination with Janssen (two doses for Group 15E) - Ad26.COV2.S at 5x1010 vp followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV-2 rS vaccine with 50 mcg Matrix-M); 2) Group 2E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 100-mcg dose of mRNA-1273, Group 5E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 8E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 30-mcg dose of BNT162b2, Group 13E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a 50-mcg dose of mRNA-1273; Group 16E - previously EUA-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV2 rS vaccine with 50 mcg Matrix-M); 3) Group 3E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 100-mcg dose of mRNA-1273. Group 6E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 5x10^10 vp dose of Ad26.COV2.S, Group 9E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 30-mcg dose of BNT162b2, Group 11E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 100-mcg dose of mRNA-1273.211. Group 14E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a 50-mcg dose of mRNA-1273, Group 17E - previously EUA-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses followed by a dose of NVX-CoV2373 (5 mcg Prototype SARS-CoV2 rS vaccine with 50 mcg Matrix-M).

A telephone visit will occur one week after each primary EUA vaccination and one week after the booster dose. In person follow-up visits will occur on 14 days following completion of EUA vaccinations and on days 14, and 28 days after the booster dose, as well as 3, 6, and 12 months post the booster vaccination. Additional pools of subjects can be included if needed as additional COVID-19 vaccines are awarded EUA.

The primary objectives of this study are 1) to evaluate the safety and reactogenicity of delayed heterologous or homologous vaccine doses after EUA dosed vaccines, and 2) to evaluate the breadth of the humoral immune responses of heterologous and homologous delayed boost regimens following EUA dosing.

Pfizer reported $10.85B in Stock for its fiscal quarter ending in December of 2024. Data for Pfizer | PFE - Stock including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Pfizer Ventures - BioCentury Company Profiles for the biopharma industry

Pfizer other current assets for the quarter ending March 31, 2025 were $5.847B, a 32.05% decline year-over-year. Pfizer other current assets for 2024 were $7.567B, a 14.87% decline from 2023. Pfizer other current assets for 2023 were $8.889B, a 3.43% increase from 2022. Pfizer other current assets for 2022 were $8.594B, a 124.97% increase from 2021.

Subscribers can find out export and import data of 23 countries by HS code or product’s name. This demo is helpful for market analysis.

Analysis of ‘COVID-19 Vaccine Distribution Allocations by Jurisdiction - Pfizer’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/38bd36a4-e102-44e8-b259-8da064880395 on 26 January 2022.

--- Dataset description provided by original source is as follows ---

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Moderna Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

--- Original source retains full ownership of the source dataset ---

Pfizer total liabilities and share holders equity for the quarter ending March 31, 2025 was $213.396B, a 5.79% decline year-over-year. Pfizer total liabilities and share holders equity for 2024 was $213.396B, a 5.79% decline from 2023. Pfizer total liabilities and share holders equity for 2023 was $226.501B, a 14.86% increase from 2022. Pfizer total liabilities and share holders equity for 2022 was $197.205B, a 8.67% increase from 2021.

Pfizer - 当前值，历史数据，预测，统计，图表和经济日历 - Jun 2025.Data for Pfizer including historical, tables and charts were last updated by Trading Economics this last June in 2025.

Pfizer - 현재 값, 이력 데이터, 예측, 통계, 차트 및 경제 달력 - Jul 2025.Data for Pfizer including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Pfizer 股票 - 当前值，历史数据，预测，统计，图表和经济日历 - Jun 2025.Data for Pfizer | 股票 including historical, tables and charts were last updated by Trading Economics this last June in 2025.

Pfizer reported $208.03B in Assets for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Assets including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Subscribers can find out export and import data of 23 countries by HS code or product’s name. This demo is helpful for market analysis.

The statistic shows the total assets of pharmaceutical company Pfizer from 2006 to 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's total assets came to some 213 billion U.S. dollars.

Pfizer's annual revenue was $63.63 B in fiscal year 2024. The annual revenue increased $5.13 B from $58.50 B (in 2023) to $63.63 B (in 2024), representing a 8.77% year-over-year growth.

In fiscal year 2024, the total number of employees at Pfizer was 81,000. The employee count decreasedby 7,000 from 88,000 (in 2023) to 81,000 (in 2024). It represents a -7.95% year-over-year decline in employee count.

Pfizer reported $2.97B in Net Income for its fiscal quarter ending in March of 2025. Data for Pfizer | PFE - Net Income including historical, tables and charts were last updated by Trading Economics this last July in 2025.

Pfizer Inc. (Pfizer) discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US. Read More